We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The epidemiology, symptoms, diagnosis and management of human T-cell lymphotropic virus types 1 and 2 (HTLV-1 and HTLV-2).
Information for healthcare professionals, patients, and the public.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
Information for patients, public and health care professionals.
Projects granted during 2016 that have a primary purpose of basic research, oncology.
Projects granted during 2016 that have a primary purpose of translational and applied research - human cancer.
Ground-breaking new cancer treatments have moved a step closer with the signing of a major agreement between the government and BioNTech SE.
Project Orbis is a programme to review and approve promising cancer drugs helping patients access treatments faster.
Projects granted during 2015 that have a primary purpose of basic research: oncology.
Chief Medical Officer for England, Professor Chris Whitty's annual reports and lectures on medicine and public health.
Volume 34 of the non-technical summaries granted under the Animals (Scientific Procedures) Act 1986 during 2013.
Following MHRA approval of a clinical trial, early breast cancer patients on endocrine-based therapy can benefit from a study with camizestrant.
Volume 21 of the non-technical summaries granted under the Animals (Scientific Procedures) Act 1986 during 2013.
Patients with recurring lymphoma, or who have not responded to prior treatments, could access a new bispecific antibody therapy to help treat their condition.
Projects granted during 2015 that have a primary purpose of basic research: immune system.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).